Celltrion is starting to supply the antibody treatment for the novel coronavirus infection (Corona 19), “Recyrona (ingredient name regdanvimab),” while the attention is focused by revealing more specifically a plan to develop a new treatment that can respond to the corona 19 mutant virus.
As a result of recent Celltrion requesting the National Institutes of Disease Control and Prevention to test for its ability to neutralize Rekirona, Rekyrona showed neutralizing ability against British mutant virus, but showed low effect against South African mutant virus.
Accordingly, Celltrion plans to complete a phase 2 clinical trial for a new antibody treatment within the next 6 months. In particular, it was revealed that candidate antibody No. 32 out of a total of 38 neutralizing antibody candidates showed neutralizing ability against British and South African mutants.
On the 17th, a Celltrion official said in a phone call with our magazine, “Antibody 32 is showing an effect on mutations in South Africa,” and “Celltrion has built a platform that can respond to mutations as it seems likely that mutations in the coronavirus will continue.” .
“We are aiming to complete phase 2 of a new treatment before the South African mutant virus rises to the dominant species,” he said. “Like Rekirona, we have conditional approval in mind.”
On the other hand, Celltrion, which started accepting supply applications for each medical institution from the 16th, started supplying them today. It will be supplied sequentially, starting with the medical institution that submitted the supply application. Celltrion Pharmaceutical, a subsidiary that has the right to supply Celltrion antibody drugs in Korea, will supply Rekirona in Korea.
The treatment is provided free of charge to patients and can be supplied by filling out a supply request form directly from 156 designated Corona 19 treatment medical institutions nationwide and applying to Celltrion Pharmaceutical.
Treatment targets are confirmed patients with COVID-19 based on the scope approved by the Ministry of Food and Drug Safety, within 7 days from the date of symptom onset, among patients who do not require oxygen therapy, age 60 or older, cardiovascular disease, chronic respiratory disease, diabetes , Hypertension, etc., or patients with pneumonia.
Celltrion has completed the production of Rekirona for 100,000 people for the purpose of treating domestic patients, and plans to produce 1.5 to 3 million people per year depending on demand.
An official from Celltrion Pharmaceutical said, “Because there are medical institutions that have already received applications, there will be medical institutions that actually receive Rekirona today.”